Skip to content
Companies

Climb Bio

B-cell depleting antibodies for autoimmune disease

Raised to date

$110.1M

of $110.1M offered across 1 Form D filing

Investors
22
Last filed
May 4, 2026

About

Climb Bio is a clinical-stage biotechnology company in Wellesley Hills, Massachusetts developing disease-modifying monoclonal antibodies for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 antibody that depletes B cells and is being developed across B-cell-mediated conditions including primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus. A second program, CLYM116, is an anti-APRIL monoclonal antibody for IgA nephropathy. The company trades publicly as CLYM and was formerly known as Eliem Therapeutics, adopting the Climb Bio name in October 2024.

Climb Bio concentrates on differentiated antibodies against validated immunology targets — CD19 B-cell depletion and APRIL — and pursues indications where patients have limited therapeutic options, particularly autoimmune kidney disease.

Funding

  • EquityFiled May 4, 2026Form D
    $110.1M/ $110.1M

Product

Budoprutug

Investigational biologic therapeutic

An investigational anti-CD19 monoclonal antibody that depletes B cells, in clinical development for B-cell-mediated autoimmune diseases including primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus.

  • Anti-CD19 monoclonal antibody mechanism
  • B-cell depleting
  • Development across multiple B-cell-mediated indications

Built for

Patients with immune-mediated diseases, particularly autoimmune kidney and hematologic conditions, reached through nephrologists, rheumatologists and hematologists

People on file